abs30.txt	background	&	aims		estimates	of	disease	burden	can	inform	national	healthpriorities	for	research		clinical	care		and	policy		we	aimed	to	estimate	healthcare	use	and	spending	among	gastrointestinal	(gi)	(including	luminal		liver		andpancreatic)	diseases	in	the	united	states	methods		we	estimated	health	care	use	and	spending	based	on	the	most	currentlyavailable	administrative	claims	from	commercial	and	medicare	supplemental	plans	data	from	the	gi	quality	improvement	consortium	registry		and	national	databases	results		in	2015		annual	health	care	expenditures	for	gastrointestinal	diseasestotaled	$135	9	billion		hepatitis	($23	3	billion)		esophageal	disorders	($18	1billion)		biliary	tract	disease	($10	3	billion)		abdominal	pain	($10	2	billion)	and	inflammatory	bowel	disease	($7	2	billion)	were	the	most	expensive		yearly	there	were	more	than	54	4	million	ambulatory	visits	with	a	primary	diagnosis	fora	gi	disease		3	0	million	hospital	admissions		and	540	500	all-cause	30-dayreadmissions		there	were	266	600	new	cases	of	gi	cancers	diagnosed	and	144	300cancer	deaths		each	year		there	were	97	700	deaths	from	non-malignant	gidiseases		an	estimated	11	0	million	colonoscopies		6	1	million	upper	endoscopies	313	000	flexible	sigmoidoscopies		178	400	upper	endoscopic	ultrasoundexaminations		and	169	500	endoscopic	retrograde	cholangiopancreatographyprocedures	were	performed	annually		among	average-risk	persons	ages	50-75	yearswho	underwent	colonoscopy		34	6%	had	1	or	more	adenomatous	polyps		4	7%	had	1	ormore	advanced	adenomatous	polyps		and	5	7%	had	1	or	more	serrated	polyps	removed	conclusions		gi	diseases	contribute	substantially	to	health	care	use	in	theunited	states		total	expenditures	for	gi	diseases	are	$135	9	billion	dollarsannually-greater	than	for	other	common	diseases		expenditures	are	likely	tocontinue	increasing	
